Page 49 - Product Testing News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Press release content from Business Wire. The AP news staff was not involved in its creation. Completion of the Third Clinical Trial - an Important Achievement for Medicortex Finland April 15, 2021 GMT TURKU, Finland--(BUSINESS WIRE)--Apr 15, 2021-- Medicortex Finland Oy, a biotechnology company developing a breakthrough biomarker-based diagnostic kit for brain injury detection, completed collection of body fluid samples in its third large clinical study. Children and adolescents were recruited who visited the hospital with a suspected mild traumatic brain injury or concussion. “Collecting ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. CytoDyn Executes Exclusive Supply and Distribution Agreement with Chiral Pharma Corporation to ... CytoDyn Inc.April 15, 2021 GMT Under Compassionate Special Permit (CSP) in Philippines, CytoDyn is well positioned to generate significant revenues VANCOUVER, Washington., April 15, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with potential multiple therapeutic indicatio...

Press release content from PR Newswire. The AP news staff was not involved in its creation. airKAVE Portable Air Purifier Now Approved To Combat COVID-19 April 15, 2021 GMT AIRKAVE PORTABLE AIR PURIFIER NOW APPROVED TO COMBAT COVID-19 LOS ANGELES, April 15, 2021 /PRNewswire/ -- airKAVE, the world’s most advanced air purification technology, announced today that the airKAVE Portable passed the Characterization of Model AH01 Air Purification Device in Deactivation of Aerosolized SARS-COV-2 test (from MRIGlobal). The test confirms that airKAVE Portable destroys aerosolized SARS-CoV-2 within a ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Affimed Reports 2020 Financial Results and Highlights Recent Operational Progress Affimed N.V.April 15, 2021 GMT AFM13 monotherapy: Reported positive data from the preplanned interim analysis for the registration-directed trial in PTCL AFM13 combination with NK cells: Announced 100% objective response rate in four response evaluable patients, including 2 complete responses AFM24 monotherapy: AFM24 (phase 1/2a study) completed cohort 4 and is enrolling and treating patients in cohort 5; expansion coh...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Reata Announces the Appointments of Christy J. Oliger and Shamim Ruff to Its Board of Directors Reata Pharmaceuticals, Inc.April 15, 2021 GMT PLANO, Texas, April 15, 2021 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced the appointments of Christy J. Oliger and Shamim Ruff to its Board of Directors, effective April 15, 2021. “We are excited to welcome Ms. Ruff and Ms. Oliger to...